From the Journals: Editors’ Picks for November
Each month, the editors from the portfolio of scientific journals published by the American Association for Cancer Research (AACR)...
Each month, the editors from the portfolio of scientific journals published by the American Association for Cancer Research (AACR)...
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes...
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
Since its inception in 1993, the American Association of Cancer Research (AACR) Grants Program, in partnership with other nonprofit...
The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S....
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted...
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...